Dr. Hanneke W.M. van Laarhoven
Medische Oncologie
Academisch Medische Centrum
Blik op de toekomst: lopende en geplande
DOCG studies
• Neoadjuvante chemoradiatie: surgery when needed
(preSANO)
• Neoadjuvante chemoradiatie: targeted treatment (TRAP)
• Neoadjuvante/definitieve chemoradiatie: surgery if
possible (TOR)
• Definitieve chemoradiatie: dosisintensificatie (ART-DECO)
• Dataregistratie (POCOP)
preSANO
pre- Surgery As Needed for Oesophageal carcinoma
A single-arm feasibility trial
Primary endpoint
• Correlation between the clinical response
during CRE-I and CRE-II and the final
pathological response in the resection
specimen
Secondary endpoints
• Serious complications during endoscopic
and endosonographic tissue sampling
• R0-resection rates for all included patients
that undergo resection
TRAP
Chemoradiation, TRAstuzumab and Pertuzumab in resectable
HER2+ esophageal carcinoma
A single arm feasibility study
Primary endpoint
• Withdrawal rate from surgery
Secondary endpoints
• pCR
• Toxicity
• Post-operative complications
TOR
Chemoradiotherapy followed by resection for
patients with gevolgd a T4b oesofagus carcinoma
Primary endpoint
•R0 resection (≥ 80% )
Secondary endpoints
•Post-operative complications
•Mortality
•Quality of life
ART-DECO
A Randomized Trial of Dose Escalation in
definitive Chemoradiotherapy for patients with
Oesophageal cancer
Landelijk Platform
Radiotherapie voor
Gastro Enterologische
tumoren
Primary endpoint
•Local recurrence rate (≥ 15%
difference)
Secondary endpoints
•Grade 3-4 toxicity
•Survival
POCOP
Prospective Observational Cohort Study of
Oesophageal-gastric cancer Patients
Acknowledgments
• Joel Shapiro, Bas Wijnhoven, Jan van Lanschot (preSANO)
• Maarten Anderegg, Mark van Berge Henegouwen (TOR)
• Maarten Hulshof (ART-DECO)
• Leonie Haverkamp, Jelle Ruurda (Oesofagus/maag parel)